

SL-01. Mcl-1 Apoptosis

Apoptosis is now considered an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents. However, their therapeutic value is undermined by significant toxicity issues. As a result, interest has grown in compounds that can selectively target a single Bcl-2 family member (such as Bcl-2 or Bcl-xL) with low toxicity. Myeloid cell leukemia 1 (Mcl-1), is overexpressed in various cancers. We were able to find several acylsulfonamide derivatives with Mcl-1 binding potency and improved physico-chemical characteristics [1,2].

Signature Library 01

Formats	Supplementary Information	
80 compounds per plate	IC ₅₀ [Mcl-1-BidBH3]	
0.1 mg; 1 mg; 2 mg dry film/powder	Solubility data in PBS	
0.1 µmol; 1 µmol DMSO solutions	SL#1_Mcl-1_04-16.sdf	

References:

1. J Med Chem. 2016 Mar 10;59(5):2054-66. doi: 10.1021/acs.jmedchem.5b01660

2. J Med Chem. 2015 Mar 12;58(5):2180-94. doi: 10.1021/jm501258m

<u>Contact us</u>: USA: Japan: Europe/Global:

+1 336 721 1617 +81-80-3401-9097

mparisi@asinex.com sota@asinex.com lsadovenko@asinex.com

asinex.com